I. INTRODUCTION
===============

Large granular lymphocyte leukemias (LGLL) are chronic clonal lymphoproliferations of mature post-thymic TCRαβ^+^ CD3^+^CD4^−^CD5^dim^CD8^+^CD27^−^CD28^−^ CD45RO^−^CD57^+^ T cells (T-LGLL, 85% of cases) or CD3^−^ CD56^+^ natural killer cells (NK-LGLL) \[[@b1-tm-15-80]--[@b5-tm-15-80]\]. T-LGLL usually affects old subjects (\> 60 years) with an indolent course and a median overall survival \> 10 years \[[@b1-tm-15-80],[@b5-tm-15-80]\]. At diagnosis, T-LGLL patients show peripheral blood (PB) cytopenias, splenomegaly, bone marrow (BM) infiltration by clonal large granular lymphocytes (LGLs), frequently associated with autoimmune or hematologic disorders (40% of cases) ([Table 1](#t1-tm-15-80){ref-type="table"}) \[[@b1-tm-15-80],[@b3-tm-15-80],[@b5-tm-15-80]\].

Current guidelines of T-LGLL suggest to start treatment only in patients with symptomatic or life-threatening cytopenias ([Table 2](#t2-tm-15-80){ref-type="table"}) \[[@b3-tm-15-80],[@b4-tm-15-80]\]. Immunosuppressive therapy (IST), with single agent methotrexate (MTX), cyclophosphamide (CTX), or cyclosporin-A (CyA), is the first-line therapy of T-LGLL.

Overall response rate with IST ranges from 40% to 70%, but no standard treatments are clearly defined due to the lack of prospective studies \[[@b3-tm-15-80]--[@b5-tm-15-80]\]. Relapsed patients after IST stop or tapering, as defined in [Table 3](#t3-tm-15-80){ref-type="table"}, are eligible for a second course of immunosuppression with similar or different IST \[[@b6-tm-15-80]\]. In T-LGLL patients with IST failure after 4 months, a switch to a second-line treatment is recommended \[[@b5-tm-15-80],[@b7-tm-15-80]\]. Bendamustine is an alkylating agent that may act as a purine analogue, but the precise mechanism of action is still unclear \[[@b8-tm-15-80]\]. This drug is largely used in B-cell non-Hodgkin lymphoma (NHL), but recent studies have focused on refractory/relapsed T cell neoplasm patients, suggesting a role of this drug also in T-cell NHL \[[@b9-tm-15-80]--[@b10-tm-15-80]\].

Here, we report two cases of elderly refractory T-LGLL patients who achieved a prolonged complete remission using bendamustine as salvage therapy.

II. PATIENTS AND METHODS
========================

In this study, two T-LGLL patients were enrolled after informed consent in accordance with the Declaration of Helsinki \[[@b11-tm-15-80]\] and the institutional review boards of the Hematology and Transplant Center, Department of Medicine and Surgery, University of Salerno, Italy. The authors retrospectively reviewed all available medical records.

III. RESULTS
============

Case 1
------

A 73-year-old woman received diagnosis of T-LGLL in 2003 from other institution. Treatment with low-dose oral MTX, (10 mg/m^2^ weekly) and prednisone (PDN) was started in 2008, due to anemia and moderate thrombocytopenia. After a 4-month therapy, in the absence of a clinical response, oral CTX (100 mg/day) and PDN for 4 months were used as second-line treatment without any response, although this therapy was associated with erythropoiesis-stimulating agents (ESAs). In August 2012, the patient referred to our institution for fatigue, transfusion-dependent severe anemia and neutropenia. The basic clinical characteristics, laboratory data on admission and clinical records of the patient are detailed in [Table 4](#t4-tm-15-80){ref-type="table"}.

In September 2012, oral CyA, (2 mg/Kg/day) and PDN were administered as third-line therapy, but the patient experienced the worsening of cytopenias, the increase in the transfusion support (8--10 packed red blood cell transfusions/month), and positivity of indirect and direct antiglobulin tests. After 8 months of no clinical response, the patient performed a salvage therapy with bendamustine (70 mg/m^2^ for 2 consecutive days every 28 days). *Pneumocystis jiroveci* prophylaxis was carried out with trimethoprim/sulfamethoxazole (TMP/SMX), while ESAs were administered to improve erythropoiesis. After the first bendamustine course, our patient experienced a rapid hemoglobin improvement and transfusion independence, achieving complete remission (CR) within three months. Grade 4 neutropenia was documented after the second course of chemotherapy and treated with granulocyte colony-stimulating factors (G-CSFs). The patient experienced also other complications such as *Escherichia coli*-related urinary tract infection (treated with 500 mg/day oral levofloxacin for 6 days) and hypertransaminasemia associated with vasculitis-like rush of the limbs after the third cycle, which led to the treatment discontinuation and patient re-evaluation. Given that the patient was in CR and showed a minimal BM infiltration (LGLs \<10% of total cellularity), bendamustine was definitely discontinued. CR was maintained for 20 months, when the patient showed again anemia; for this reason, a second course of 4 cycles of bendamustine was administered, without any clinical toxicity. At last follow-up, 12 months after the end of therapy, the patient was still in CR.

Case 2
------

A 72-year-old man was admitted to our department in October 2013 for severe anemia associated with atypical circulating and marrow LGLs ([Figure 1A](#f1-tm-15-80){ref-type="fig"}). Physical examination did not detected lymphadenopathies and hepatomegaly, but revealed splenomegaly, confirmed by ultrasonography (longitudinal diameter, 150 mm; anteroposterior diameter, 156 mm; transverse diameter, 66 mm). Other clinical characteristics, laboratory data on admission and clinical records of the patient are summarized in [Table 4](#t4-tm-15-80){ref-type="table"}. Immunosuppression was started with CyA (5 mg/Kg/day) and PDN (0.5 mg/kg/day). After a 4-month therapy, the persistence of transfusion-dependent anemia and the worsening of neutropenia (0.29 × 10^9^ cells/L) required a second line therapy. Bendamustine was administrated for a total of 6 cycles at 70 mg/m^2^ for 2 days every 28 days. Bacterial, fungal and *Pneumocystis jiroveci* prophylaxis was carried out using oral levofloxacin (500 mg/day), oral fluconazole (200 mg/day), and TMP/SMX (160--800 mg/twice per week). ESAs and G-CSFs were also administered to reduce myelosuppression and to prevent febrile neutropenia. Grade 3 neutropenia and two episodes of transient hypertransaminasemia with indirect hyperbilirubinemia were documented, but they did not require drug discontinuation. CR was achieved after 6 cycles of bendamustine and, after that, the patient no longer needed transfusions or ESAs administration ([Figure 1B](#f1-tm-15-80){ref-type="fig"}). BM aspiration performed at the end of treatment did not show evidence of lymphoproliferative disorder, confirmed by BM flow cytometry immunophenotype and BM biopsy. After 26-month of follow-up, the patient was still in CR.

IV. DISCUSSION
==============

T-LGLL is a chronic lymphoproliferative disorder with an indolent course, mostly diagnosed after the sixtieth decade of life^1^. T-LGLL patients are a fragile population because of their older age (\>60-year-old), the presence of comorbidities (frequently autoimmune disorders) and symptoms which negatively influence the quality of life and the outcome \[[@b12-tm-15-80],[@b13-tm-15-80]\]. Nowadays, there are no "curative" therapeutic options for T-LGLL. For this reason, the goals are the stabilization of the disease and the correction of cytopenias. IST is the mainstay of treatment for T-LGLL \[[@b3-tm-15-80],[@b5-tm-15-80]\], but the optimal therapeutic strategy for refractory/relapsed patients is still challenging, even though purine analogues and alemtuzumab are currently used as second-line therapy^4^.

Bendamustine, a molecule developed more than 50 years ago, is an alkylating agent with a complex mechanism of action, sharing characteristics with purine analogues \[[@b8-tm-15-80],[@b11-tm-15-80]\]. Several mechanisms of action have been hypothesized, as the induction of extensive and durable DNA damage and impairment of DNA repair \[[@b8-tm-15-80]\]. The inhibition of the DNA repair mechanism could be enhanced by the *in vitro* combination of bendamustine with cladribine or fludarabine, commonly used for B-cell and T-cell NHL \[[@b8-tm-15-80],[@b14-tm-15-80]\]. Bendamustine can induce apoptosis through traditional and non-traditional pathways \[[@b8-tm-15-80]\]. In particular, the activation of mitotic catastrophe is caspase-2-dependent and cannot be inhibited by overexpression of Bcl-2 \[[@b8-tm-15-80]\]. Moreover, the p53-dependent DNA-damage response pathways can be activated not only by bendamustine-induced DNA interstrand crosslinks, but also by oxidative stress and increased release of apoptosis-inducing factor from mitochondria \[[@b8-tm-15-80]\]. Based on the interesting results of Zaja et al. in 2013 in a small cohort of T-cell NHL refractory/relapsed patients, we decided to start bendamustine administration in two cases of refractory T-LGLL patients, according to the dosage previously reported \[[@b9-tm-15-80]\]. Furthermore, bendamustine was chosen as salvage therapy due to its mechanism of action, hypothesizing that the mitotic catastrophe could avoid the constitutively activated anti-apoptotic pathways in LGLs \[[@b8-tm-15-80]\]. Indeed, our series of refractory T-LGLL patients experienced a rapid clinical response and achieved the CR within 3 and 6 months, respectively. One patient relapsed after 20 months of CR with a minimal BM LGL infiltration. Interestingly, she was still responsive to a second course of bendamustine which allowed a 12-months disease-free survival at the time of writing. Moreover, bendamustine was confirmed as a drug with a good safety profile \[[@b14-tm-15-80]\], because the myelosuppression was easily managed with G-CSFs and ESAs.

V. CONCLUSION
=============

Standard salvage treatment for relapsed/refractory T-LGLL patients has not been defined yet due to the lack of prospective studies. Bendamustine-based regimens are increasingly used in both B-cell and T cell neoplasms, but few studies are available for T-LGLL. Our case series shows the efficacy and safety of bendamustine in the treatment of elderly relapsed/refractory T-LGLL patients. Even though these results require further validation in prospective randomized studies, bendamustine as single agent or in combination should be considered a feasible second-line option for relapsed or refractory T-LGLL.

![Bone marrow morphological features and clinical course in case 2 T-LGLL.\
(A) Marrow large granular lymphocytes with abundant cytoplasm and the characteristic azurophilic granules (May--Giemsa assay, Nikon Microscope, Ci-L model; original magnification 20× left panel, and 100× right panel).\
(B) Hemoglobin levels during and after bendamustine treatment. Red blood cell transfusions are displayed as dark red arrow, according to the time of administration.](tm-15-80-i001){#f1-tm-15-80}

###### 

LGLL diagnostic criteria \[[@b3-tm-15-80],[@b5-tm-15-80]\]

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical presentation:PB cytopenia(s)SplenomegalyAutoimmune diseasesLGL \> 0.5 × 10^9^ cells/LLGL morphology:Large dimensions (15--18 um of diameter)Round or reniform nucleusAbundant cytoplasm with azurophilic granulesLGL phenotype:*T: TCRαβ^+^CD3^+^CD4^−^CD5^dim^CD8^+^CD27^−^CD28^−^CD45RO^−^CD57^+^NK: CD3^−^CD16^+^CD56^+^CD57^+^*Presence of clonal TCR rearrangement by PCR or flow cytometry
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations.** LGLL = large granular lymphocyte leukemia; PB = peripheral blood; LGL = large granular lymphocytes; TCR = T cell receptor; NK = natural killer cell; PCR = polymerase chain reaction.

###### 

Treatment indications in LGLL \[[@b3-tm-15-80],[@b5-tm-15-80]\]

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Severe neutropenia (absolute neutrophil count \<0.5×10^9^ cells/L)Moderate neutropenia (absolute neutrophil count \<1×10^9^ cells/L) with recurrent infectionsSymptomatic or transfusion dependent anemiaSevere thrombocytopenia (\<0.5 × 10^9^/L)Associated autoimmune conditions requiring therapy
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations.** LGLL = large granular lymphocyte leukemia.

###### 

Response criteria in LGLL \[[@b3-tm-15-80]\]

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Complete response:**Hemoglobin \>12 g/dLPlatelet count ≥150 × 10^9^/LANC \>1.5 × 10^9^ cells/LALC \<4 × 10^9^ cells/L with circulating LGLs \< 0.5 × 10^9^ cells/L
  **Partial response:**Improvements of blood count that do not meet criteria for CRANC \>0.5×10^9^ cells/L or decreasing transfusion requirements
  **Treatment failure:**Failure to achieve partial or complete response
  **Progressive disease:**Worsening of cytopenias, hepatomegaly or splenomegaly
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations.** LGLL = large granular lymphocyte leukemia; ANC = Absolute neutrophil count; ALC = Absolute lymphocyte count; LGLs = large granular lymphocytes; CR = complete remission.

###### 

Patients characteristics

                                                   Case 1                                              Case 2
  ------------------------------------------------ --------------------------------------------------- ------------------------------------------------------
  • **Age**                                        73                                                  72
  • **Sex**                                        Female                                              Male
  • **Laboratory data on admission**                                                                   
   Hemoglobin g/dL                                 7.7                                                 8.8
   White blood cell (× 10^9^ cells/L)              7.01                                                11.19
   Absolute lymphocyte count (× 10^9^ cells/L)     5.41                                                10.17
   Absolute neutrophil count (× 10^9^ cells/L)     1.10                                                0.615
   Platelet count (× 10^9^cells/L)                 224                                                 117
   Mean corpuscular volume (fL)                    112                                                 104
   Lactate dehydrogenase (U/L)                     644                                                 776
   Rheumatoid factor                               Negative                                            n.e.
   Anti-nuclear antibodies titer                   1:640                                               n.e.
   Direct antiglobulin test                        Negative                                            Negative
  • **Peripheral blood LGLs**                                                                          
   Percentage (%)                                  75                                                  78
   Flow cytometric phenotype                       CD3^+^CD8^+^CD7^+^CD5^−^CD4^−^CD56^−^TCRαβ^+^       CD3^+^CD8^+^CD2^+^CD7^+^CD4^−^CD5^−^CD56^−^ TCRαβ^+^
  • **Indications for treatment**                  Transfusion dependent anemia                        Transfusion dependent anemia, splenomegaly
  • **Immunosuppressive therapies**                MTX+ PDN, CTX+PDN, CyA+ PDN                         CyA+PDN
  • **Response to immunosuppressive therapies**    Treatment failure                                   Treatment failure
  • **Time to-BENDA treatment**                    10 years                                            4 months
  • **BENDA dosage**                               70 mg/m^2^ for 2 days every 28 days                 70 mg/m^2^ for 2 days every 28 days
  • **Number of BENDA cycles**                     3 and 4[\*](#tfn6-tm-15-80){ref-type="table-fn"}    6
  • **Response to BENDA**                          Complete response                                   Complete response
  • **Follow up (months) after BENDA treatment**   20 and 12[∘](#tfn7-tm-15-80){ref-type="table-fn"}   26

**Abbreviations.** n.e. = not evaluated; LGLs = large granular lymphocytes; MTX = methotrexate; PDN = prednisone; CTX = cyclophosphamide; CyA = cyclosporine-A; BENDA = bendamustine.

**Symbols**.

= 3 cycles of BENDA and 4 after relapse;

= 20 months after first BENDA treatment and 12 after the second BENDA treatment.
